Biotech

since the development and completion of the Human Genome. With other mammal genomes on the way, soon many of the pharmacological models for human drug design will experience greater completion of target to delivery speeds; a feat already dramatically improved by computer bioinformatics. Even as biochemistry better establishes and enumerates the subtleties of clinical pharmacology, regulatory delay still imposes a bottleneck for drug developers. Indeed as science improves and overcomes either the physical or regulatory boundaries of drug development, medical science is still lacking in many facets of disease management. While technology has made dramatic strides since the x-ray, we are still a long way away from truly synergistic treatments of the complex human body. The most recent in diagnostic developments, NMR, and SPECT, derive their formulary basis from research in the 1970’s and 1980’s; in fields as varied as oncology to physiology. Yet as the new technologies approach the medical marketplace, barriers to commerce imposed by regulatory agencies or economics still prevent many of the new and exciting technologies being developed in today’s Universities, from reaching the patients of tomorrow.